[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 21 of about 21
1. Lordan JT, Riga A, Worthington TR, Karanjia ND: Early and long-term outcomes of patients undergoing liver resection and diaphragm excision for advanced colorectal liver metastases. Ann R Coll Surg Engl; 2009 Sep;91(6):483-8
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Early and long-term outcomes of patients undergoing liver resection and diaphragm excision for advanced colorectal liver metastases.
  • INTRODUCTION: At present, liver resection offers the best long-term outcome and only chance for cure in patients with colorectal liver metastases.
  • However, there are no large series that report the early and long-term outcomes of patients who require simultaneous diaphragm excision.
  • Of these, 258 had liver resections alone and 27 underwent liver resection and simultaneous diaphragm excision.
  • The diaphragm was histologically involved in four out of 27 resections.
  • As a result, the cancer involved resection margin incidence was greater in the liver resection and diaphragm excision group (14.8% versus 3.9%; P = 0.12).
  • The liver and diaphragm resection group had a greater peri-operative complication rate (44.4% versus 21.3%; P = 0.02) and mortality (7.4% versus 1.6%; P = 0.25).
  • Overall and disease-free survival was significantly worse in the group who underwent simultaneous diaphragm excision and liver resection (P = 0.04 and P = 0.005, respectively).
  • Diaphragm invasion was found to be an independent predictor of poor overall outcome (P = 0.02).
  • CONCLUSIONS: Liver resection and simultaneous diaphragm excision have a greater incidence of peri-operative morbidity and mortality and a significantly worse long-term outcome compared with liver resection alone.
  • However, these data suggest that liver resection in the presence of diaphragm invasion may still offer a favourable outcome compared with chemotherapy treatment alone.
  • Therefore, we believe that diaphragm involvement by tumour should not be a contra-indication to hepatectomy.
  • [MeSH-major] Colorectal Neoplasms / pathology. Diaphragm / surgery. Hepatectomy / methods. Liver Neoplasms / surgery. Muscle Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Length of Stay. Male. Middle Aged. Retrospective Studies. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Gastrointest Surg. 2000 Jul-Aug;4(4):349-53; discussion 353-4 [11058852.001]
  • [Cites] Eur J Surg Oncol. 2009 Aug;35(8):838-43 [19010633.001]
  • [Cites] J Clin Oncol. 2002 Mar 15;20(6):1499-505 [11896097.001]
  • [Cites] Br J Surg. 2004 Mar;91(3):327-33 [14991634.001]
  • [Cites] N Engl J Med. 2004 Jun 3;350(23):2335-42 [15175435.001]
  • [Cites] N Engl J Med. 2004 Jul 22;351(4):337-45 [15269313.001]
  • [Cites] Br J Cancer. 1977 Jan;35(1):1-39 [831755.001]
  • [Cites] Cancer. 1993 Jun 15;71(12 Suppl):4252-66 [8508388.001]
  • [Cites] J Clin Oncol. 1994 Jul;12(7):1491-6 [8021741.001]
  • [Cites] Am J Med Qual. 1995 Spring;10(1):48-54 [7727988.001]
  • [Cites] Arch Surg. 1997 May;132(5):505-10; discussion 511 [9161393.001]
  • [Cites] Br J Surg. 1997 Jul;84(7):977-80 [9240140.001]
  • [Cites] Br J Surg. 1997 Aug;84(8):1136-40 [9278662.001]
  • [Cites] Ann Surg Oncol. 2005 Nov;12(11):900-9 [16184442.001]
  • [Cites] Br J Cancer. 2006 Apr 10;94(7):982-99 [16538219.001]
  • [Cites] Ann Surg Oncol. 2006 May;13(5):668-76 [16523369.001]
  • [Cites] Ann Oncol. 2006 Sep;17(9):1399-403 [16873427.001]
  • [Cites] Br J Surg. 2006 Oct;93(10):1192-201 [16983740.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2006 Dec 1;66(5):1384-90 [16979839.001]
  • [Cites] Semin Oncol. 2006 Oct;33(5 Suppl 10):S8-14 [17145525.001]
  • [Cites] Oncology (Williston Park). 2006 Dec;20(14 Suppl 10):11-9 [17354513.001]
  • [Cites] Lancet. 2008 Mar 22;371(9617):1007-16 [18358928.001]
  • [Cites] J Surg Oncol. 2008 Sep 15;98(4):263-7 [18726889.001]
  • [Cites] Chirurg. 2001 May;72(5):547-60 [11383067.001]
  • (PMID = 19558763.001).
  • [ISSN] 1478-7083
  • [Journal-full-title] Annals of the Royal College of Surgeons of England
  • [ISO-abbreviation] Ann R Coll Surg Engl
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2966200
  •  go-up   go-down


2. Butte JM, Torres J, Duarte I, Zúñiga A: [Composite tumor of the colon with liver metastases]. Cir Esp; 2007 Aug;82(2):128-30
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Composite tumor of the colon with liver metastases].
  • Treatment is similar to that of adenocarcinomas.
  • A computed tomography (CT) scan showed a tumor at the splenic flexure bowel and 2 hepatic nodules, suggesting metastases.
  • Extended right colectomy was performed, followed by an ileal-sigmoid anastomosis, resection of a diaphragm segment, and resection of both hepatic metastases.
  • Histological analysis showed moderately differentiated tubular adenocarcinoma combined with a poorly differentiated neuroendocrine carcinoma and metastases in 25 of 28 lymph nodes.
  • The 2 hepatic metastases showed areas of poorly differentiated neuroendocrine carcinoma.
  • The patient is currently asymptomatic and is undergoing chemotherapy.
  • [MeSH-minor] Adult. Female. Humans. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17785149.001).
  • [ISSN] 0009-739X
  • [Journal-full-title] Cirugía española
  • [ISO-abbreviation] Cir Esp
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


3. Song SY, Kim WS, Lee HR, Jung HS, Oh SY, Kim JH, Kim K, Nam EM, Oh YR, Jung CW, Yoon SS, Im YH, Lee HG, Kang WK, Park CH, Park K: Adenocarcinoma of unknown primary site. Korean J Intern Med; 2002 Dec;17(4):234-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Metastatic cancer of unknown primary site occupies 0.5-10% of all diagnosed cancer patients and includes various tumors with diverse responses to systemic chemotherapy.
  • Adenocarcinoma of unknown primary site (ACUPS), the most common subtype, has no standard treatment, rarely responds to conventional treatment and has a poor survival rate.
  • METHODS: The retrospective study was performed to investigate the clinical characteristics and the treatment outcomes of ACUPS.
  • The common sites of metastases were the lymph node, liver, lung and bone in order.
  • In 49 of 81 patients (60.5%), the dominant tumor location was below the diaphragm.
  • The majority of patients (76 of 81) were initially treated with systemic chemotherapy including cisplatin.
  • Eighteen of 70 patients (25.7%) responded to chemotherapy and complete remission was observed in 6 patients.
  • In univariate and multivariate analysis, age, performance status and response to initial chemotherapy were significant prognostic factors for overall survival.
  • CONCLUSION: We observed poor response to the treatment and survival rate in ACUPS, but complete remission and long-term survival were observed in a small number of patients.
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / secondary. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Neoplasms, Unknown Primary / drug therapy. Neoplasms, Unknown Primary / pathology
  • [MeSH-minor] Adult. Aged. Female. Humans. Male. Middle Aged. Retrospective Studies. Survival Analysis. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12647637.001).
  • [ISSN] 1226-3303
  • [Journal-full-title] The Korean journal of internal medicine
  • [ISO-abbreviation] Korean J. Intern. Med.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC4531687
  •  go-up   go-down


Advertisement
4. Terauchi F, Moritake T, Yamamoto Y, Ogura H: Combination chemotherapy with paclitaxel and intraperitoneal cisplatin for ovarian cancer with disseminated lesions in the peritoneum and the diaphragm. Int J Clin Oncol; 2002 Dec;7(6):356-60
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combination chemotherapy with paclitaxel and intraperitoneal cisplatin for ovarian cancer with disseminated lesions in the peritoneum and the diaphragm.
  • METHODS: Twelve patients with progressive epithelial ovarian cancer (FIGO IIIc), which was resected using an optimal method at primary surgery, except for disseminated lesions in the peritoneum and the diaphragm, were studied.
  • If metastases were identified in the diaphragm, then another reservoir was also placed in the subdiaphragm (double reservoirs).
  • The response to the therapy was evaluated with tumor markers, and by using cytodiagnoses on the peritoneal washing fluid collected from the reservoirs.
  • RESULTS: After five courses of the chemotherapy, the tumor marker levels and cytodiagnoses of all patients became negative.
  • CONCLUSION: The combination chemotherapy with intravenous PAC and intraperitoneal CDDP was effective on ovarian cancer with disseminated lesions in the peritoneum and the diaphragm, having only mild adverse effects.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Diaphragm. Muscle Neoplasms / secondary. Ovarian Neoplasms / drug therapy. Peritoneal Neoplasms / secondary

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12494251.001).
  • [ISSN] 1341-9625
  • [Journal-full-title] International journal of clinical oncology
  • [ISO-abbreviation] Int. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / Biomarkers, Tumor; 0 / CA-19-9 Antigen; 0 / Carcinoembryonic Antigen; P88XT4IS4D / Paclitaxel; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


5. Gassiamis A, Tsakonas G, Soukouli G, Mylonakis N, Karabelis A, Kosmas C: Diffuse calcification of metastases after intensive multiagent chemotherapy in widespread osteosarcoma leading to death in a 18-year-old male: report of a case and literature review. Med Oncol; 2006;23(4):455-62
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diffuse calcification of metastases after intensive multiagent chemotherapy in widespread osteosarcoma leading to death in a 18-year-old male: report of a case and literature review.
  • Multifocal osteosarcoma represents a rare and aggressive type of osteosarcoma in which multiple bone lesions are detected simultaneously in the absence of pulmonary or any other visceral organ involvement.
  • Here we report a case of an 18-yr-old patient with extensively metastatic osteosarcoma developing diffuse calcification in lung, pleural, diaphragm, pericardial, subcutaneous metastases, and mediastinal lymph nodes after intensive multiagent chemotherapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bone Neoplasms / drug therapy. Bone Neoplasms / pathology. Calcinosis. Osteosarcoma / drug therapy. Osteosarcoma / secondary
  • [MeSH-minor] Adolescent. Combined Modality Therapy. Fatal Outcome. Humans. Magnetic Resonance Imaging. Male. Neoplasm Metastasis. Neoplasms, Multiple Primary / classification. Neoplasms, Multiple Primary / pathology. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Osteosarcoma.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Cancer Res. 2004 Dec 1;10(23):8114-9 [15585647.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 May 1;89(9):4207-9 [1349175.001]
  • [Cites] Jpn J Clin Oncol. 2001 Nov;31(11):562-6 [11773266.001]
  • [Cites] Skeletal Radiol. 1997 Oct;26(10 ):569-78 [9361352.001]
  • [Cites] Ann Oncol. 1996 Oct;7(8):864-6 [8922204.001]
  • [Cites] Cancer. 2003 Dec 1;98(11):2457-66 [14635081.001]
  • [Cites] J Bone Joint Surg Br. 1957 Aug;39-B(3):524-33 [13463042.001]
  • [Cites] Clin Exp Metastasis. 2004;21(8):747-53 [16035619.001]
  • [Cites] Arch Intern Med. 1966 Sep;118(3):203-4 [5222321.001]
  • [Cites] Clin Cancer Res. 2005 Apr 1;11(7):2561-7 [15814634.001]
  • [Cites] Clin Cancer Res. 2003 Dec 15;9(17):6560-6 [14695161.001]
  • [Cites] Cancer Metastasis Rev. 1989 Aug;8(2):98-101 [2673568.001]
  • [Cites] Cancer. 1969 Nov;24(5):923-31 [5260741.001]
  • [Cites] J Chemother. 2001 Jun;13(3):324-30 [11450892.001]
  • [Cites] Surgery. 1978 Aug;84(2):231-40 [278229.001]
  • [Cites] Cancer. 1979 Nov;44(5):1897-907 [387210.001]
  • [Cites] Mayo Clin Proc. 2004 Mar;79(3):318-25 [15008605.001]
  • [Cites] Cancer Res. 1992 Nov 15;52(22):6194-9 [1423262.001]
  • [Cites] Clin Cancer Res. 2005 Jan 15;11(2 Pt 1):490-7 [15701832.001]
  • [Cites] J Surg Oncol. 1983 Apr;22(4):236-45 [6572771.001]
  • [Cites] Biochem Cell Biol. 2005 Feb;83(1):36-48 [15746965.001]
  • [Cites] J Exp Med. 2003 Nov 3;198(9):1381-9 [14597737.001]
  • [Cites] J Bone Joint Surg Am. 1990 Jan;72 (1):60-8 [2295674.001]
  • [Cites] J Bone Joint Surg Am. 1973 Apr;55(3):595-605 [4512956.001]
  • [Cites] Med Pediatr Oncol. 1993;21(2):111-6 [8433676.001]
  • [Cites] J Clin Oncol. 2003 Jan 15;21(2):342-8 [12525528.001]
  • [Cites] Oncol Rep. 2002 Jan-Feb;9(1):171-5 [11748477.001]
  • (PMID = 17303903.001).
  • [ISSN] 1357-0560
  • [Journal-full-title] Medical oncology (Northwood, London, England)
  • [ISO-abbreviation] Med. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


6. Schneider BJ, El-Rayes B, Muler JH, Philip PA, Kalemkerian GP, Griffith KA, Zalupski MM: Phase II trial of carboplatin, gemcitabine, and capecitabine in patients with carcinoma of unknown primary site. Cancer; 2007 Aug 15;110(4):770-5
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The objective response rate was 39.4% (95% CI, 22.9%-57.9%) in all patients, 36.4% in 22 patients with well to moderately differentiated adenocarcinoma, and 40.0% in 20 patients with liver metastases.
  • Median progression-free survival time was 6.2 months (95% CI, 5.4%-8.0%), and median survival time was 7.6 months (95% CI, 6.3-14.1).
  • CONCLUSIONS: The combination of carboplatin, gemcitabine, and capecitabine is active in CUP, especially in patients with liver metastases.
  • This regimen may be a potential therapy for CUP patients with good performance status, particularly those with a suspected origin below the diaphragm.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Neoplasms, Unknown Primary / drug therapy
  • [MeSH-minor] Abdominal Neoplasms / drug therapy. Abdominal Neoplasms / secondary. Adult. Aged. Anemia / chemically induced. Capecitabine. Carboplatin / administration & dosage. Carboplatin / adverse effects. Carcinoembryonic Antigen / blood. Deoxycytidine / administration & dosage. Deoxycytidine / adverse effects. Deoxycytidine / analogs & derivatives. Female. Fluorouracil / administration & dosage. Fluorouracil / adverse effects. Fluorouracil / analogs & derivatives. Humans. Kaplan-Meier Estimate. Leukopenia / chemically induced. Liver Neoplasms / drug therapy. Liver Neoplasms / secondary. Lung Neoplasms / drug therapy. Lung Neoplasms / secondary. Male. Middle Aged. Neutropenia / chemically induced. Treatment Outcome

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CAPECITABINE .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17594717.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Carcinoembryonic Antigen; 0W860991D6 / Deoxycytidine; 6804DJ8Z9U / Capecitabine; B76N6SBZ8R / gemcitabine; BG3F62OND5 / Carboplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


7. Debnath J, Chawla N, Talwar R, Vohra LS, George RA, Singh HP, Vaidya A, Satija L: Pleural and transdiaphragmatic retroperitoneal metastasis developing two and half years after resection of invasive thymoma. Singapore Med J; 2008 Mar;49(3):e64-7

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We report transdiaphragmatic pleural and retroperitoneal metastasis developing two and half years after resection of invasive thymoma (Masaoka stage III; WHO type B1, lymphocyte-rich) in a 34-year-old man.
  • Post-surgery, he received radiotherapy and chemotherapy.
  • Follow-up computed tomography (CT) one year post-surgery did not reveal any local recurrence or metastasis.
  • A follow-up CT done two and half years later revealed an enhancing retrocrural-retroperitoneal (posterior pararenal space) soft tissue mass measuring 12 cm x 10 cm x 6 cm.
  • Histopathology confirmed these lesions to be metastases from the lymphocyte-rich thymoma.
  • [MeSH-major] Diaphragm / pathology. Pleural Neoplasms / secondary. Retroperitoneal Neoplasms / secondary. Thymoma / pathology
  • [MeSH-minor] Adult. Humans. Male. Military Personnel. Singapore. Time Factors. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18362988.001).
  • [ISSN] 0037-5675
  • [Journal-full-title] Singapore medical journal
  • [ISO-abbreviation] Singapore Med J
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Singapore
  •  go-up   go-down


8. Katz MH, Bouvet M, Takimoto S, Spivack D, Moossa AR, Hoffman RM: Selective antimetastatic activity of cytosine analog CS-682 in a red fluorescent protein orthotopic model of pancreatic cancer. Cancer Res; 2003 Sep 1;63(17):5521-5
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Tumor RFP fluorescence facilitated real-time, sequential imaging, and quantification of primary and metastatic growth and dissemination in vivo.
  • Mice were treated with various p.o. doses of CS-682 on a five times per week schedule until death.
  • CS-682 also decreased the development of malignant ascites and the formation of metastases, which were reduced significantly in number in the diaphragm, lymph nodes, liver, and kidney.
  • Selective RFP tumor fluorescence enabled noninvasive real-time comparison between groups during treatment and facilitated identification of micrometastases in solid organs at autopsy.
  • [MeSH-major] Arabinonucleosides / pharmacology. Cytosine / analogs & derivatives. Cytosine / pharmacology. Luminescent Proteins / metabolism. Pancreatic Neoplasms / drug therapy
  • [MeSH-minor] Animals. Cell Division / drug effects. Cell Division / physiology. Humans. Male. Mice. Mice, Nude. Microscopy, Fluorescence. Neoplasm Metastasis. Transduction, Genetic. Tumor Cells, Cultured. Weight Loss / drug effects. Xenograft Model Antitumor Assays

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14500389.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P30 CA23100-1851
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Arabinonucleosides; 0 / Luminescent Proteins; 0 / red fluorescent protein; 0 / sapacitabine; 8J337D1HZY / Cytosine
  •  go-up   go-down


9. Karanjia ND, Lordan JT, Fawcett WJ, Quiney N, Worthington TR: Survival and recurrence after neo-adjuvant chemotherapy and liver resection for colorectal metastases: a ten year study. Eur J Surg Oncol; 2009 Aug;35(8):838-43
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Survival and recurrence after neo-adjuvant chemotherapy and liver resection for colorectal metastases: a ten year study.
  • BACKGROUND: Currently liver resection offers the only potential cure for colorectal liver metastases (CRLM).
  • We prospectively audited the outcome of CRLM treated by a combination of neo-adjuvant chemotherapy and surgery.
  • Patients received chemotherapy preoperatively for synchronous and early (< 2 years) metachronous metastases.
  • Patients with macroscopic diaphragm invasion by tumour, CEA > 100 ng/ml, tumour size > 5 cm or cancer involved resection margins (CIRM) had a significantly worse overall survival.
  • CONCLUSIONS: Neo-adjuvant chemotherapy followed by liver surgery is associated with improved survival and low CIRM and re-resection rates.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Colorectal Neoplasms / pathology. Liver Neoplasms / drug therapy. Liver Neoplasms / surgery. Neoplasm Recurrence, Local
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Hepatectomy. Humans. Male. Middle Aged. Neoadjuvant Therapy. Prognosis. Survival Analysis

  • Genetic Alliance. consumer health - TEN.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19010633.001).
  • [ISSN] 1532-2157
  • [Journal-full-title] European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  • [ISO-abbreviation] Eur J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


10. Mori T, Yoshioka M, Iwatani K, Kobayashi H, Yoshimoto K, Nomori H: Kissing pleural metastases from metastatic osteosarcoma of the lung. Ann Thorac Cardiovasc Surg; 2006 Apr;12(2):129-32
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Kissing pleural metastases from metastatic osteosarcoma of the lung.
  • Two patients with osteosarcoma lung metastases of which migrated to the parietal pleura due to contact are reported.
  • The first patient was a 16-year-old male who had a pleural metastasis in the diaphragm within an area in contact with a single lung metastasis.
  • Both of the tumors were resected, followed by systemic chemotherapy.
  • Nine months after the resection of the first metastases, two other lung metastases were found which were resected after chemotherapy.
  • The patient is alive without recurrence 84 months after the first resection of the metastases.
  • The second patient was an 11-year-old female with a pleural metastasis of osteosarcoma which was within an area in contact with a single lung metastasis, which had been resected 4 months before.
  • We concluded (1) that a lung metastasis of osteosarcoma occasionally metastasizes to the pleura due to contact; and (2) that because this kissing metastases of osteosarcoma could be cured by a complete resection, the intrathoracic cavity should be thoroughly observed.
  • [MeSH-minor] Adolescent. Antineoplastic Agents / therapeutic use. Child. Female. Femur / pathology. Humans. Male. Neoplasm Metastasis. Treatment Outcome

  • Genetic Alliance. consumer health - Osteosarcoma.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16702936.001).
  • [ISSN] 1341-1098
  • [Journal-full-title] Annals of thoracic and cardiovascular surgery : official journal of the Association of Thoracic and Cardiovascular Surgeons of Asia
  • [ISO-abbreviation] Ann Thorac Cardiovasc Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


11. Raney RB, Anderson JR, Andrassy RJ, Crist WM, Donaldson SS, Maurer HM, Intergroup Rhabdomyosarcoma Study Group: Soft-tissue sarcomas of the diaphragm: a report from the Intergroup Rhabdomyosarcoma Study Group from 1972 to 1997. J Pediatr Hematol Oncol; 2000 Nov-Dec;22(6):510-4
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Soft-tissue sarcomas of the diaphragm: a report from the Intergroup Rhabdomyosarcoma Study Group from 1972 to 1997.
  • PURPOSE: To describe clinical details and outcome of children and adolescents with primary sarcomas of the diaphragm treated on Intergroup Rhabdomyosarcoma Studies (IRS) I through IV.
  • PATIENTS AND METHODS: We reviewed the records of 15 patients with sarcoma of the diaphragm who were entered on IRS Group protocols between 1972 and 1997.
  • RESULTS: Localized, gross residual disease after initial surgery was present in 10 patients, and five had metastases at diagnosis (pleura, 3; pericardium, 1; lungs and bones, 1).
  • Treatment consisted of radiation therapy to the primary tumor and metastases when feasible, and combination chemotherapy with vincristine, actinomycin D, and cyclophosphamide with or without doxorubicin, ifosfamide, cisplatin, and etoposide.
  • However, the other 10 patients experienced relapse at 0.3 to 2 years from start of therapy (median, 1 yr).
  • CONCLUSIONS: Sarcomas of the diaphragm are generally deemed unresectable at diagnosis and/or are metastatic.
  • Treatment with more effective primary chemotherapy to shrink the tumor, followed-up by surgical resection and radiation therapy, should improve the prognosis for patients with sarcomas arising in the diaphragm, especially for the majority who have localized tumors.
  • [MeSH-major] Muscle Neoplasms / therapy. Rhabdomyosarcoma / therapy
  • [MeSH-minor] Adolescent. Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Child. Child, Preschool. Diaphragm. Female. Humans. Infant. Male. Radiotherapy Dosage. Recurrence. Retrospective Studies. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11132218.001).
  • [ISSN] 1077-4114
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA-24507; United States / NCI NIH HHS / CA / CA-72989
  • [Publication-type] Journal Article; Multicenter Study; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  •  go-up   go-down


12. Aoyagi H, Uetake H, Ishikawa T, Kobayashi H, Higuchi T, Yasuno M, Sugihara K: [A case report of lipoma-like tumor during hepatic arterial infusion chemotherapy]. Gan To Kagaku Ryoho; 2008 Nov;35(12):2141-3
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case report of lipoma-like tumor during hepatic arterial infusion chemotherapy].
  • Multiple hepatic metastases were observed 1 year and 10 months after the operation.
  • Hepatic arterial infusion chemotherapy was started, and a complete response for liver metastases had been continuing for 2 years.
  • On the seventh month after the hepatic arterial infusion chemotherapy was started, a lipoma-like tumor of approximately 10 cm was found under the diaphragm on the left side.
  • Two years and two months after hepatic arterial infusion chemotherapy was begun, the patient was hospitalized for excision of the tumor.
  • Intraoperative findings indicated that there was a 3.5 cm mass in the greater omentum in addition to the aforementioned tumor under the left diaphragm.
  • The histopathological findings showed that the tumor under the left diaphragm was composed of adipose tissue with coagulative necrosis.
  • The existing adipose tissue was thought to have necroses and had become encapsulated.
  • We speculated that the lipoma-like tumor was formed by the angitis with the change of the drug distribution.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Hepatic Artery. Lipoma / complications. Liver Neoplasms / drug therapy. Liver Neoplasms / secondary
  • [MeSH-minor] Aged. Colonic Neoplasms / drug therapy. Colonic Neoplasms / pathology. Colonic Neoplasms / surgery. Humans. Infusions, Intra-Arterial. Magnetic Resonance Imaging. Male

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19106550.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


13. Balat O: Paclitaxel/carboplatin versus cyclophosphamide/carboplatin in peritoneal carcinomatosis of the ovary. Eur J Gynaecol Oncol; 2004;25(2):195-6
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The preceding platinum-based combination chemotherapy could possibly reduce tumor masses, allowing for adequate surgical debulking in advanced ovarian cancer.
  • Forty-one percent of the patients (8/18) were administered six cycles of carboplatin/cyclophosphamide (CP) and the rest were administered six cycles of paclitaxel/carboplatin (TP) as a neoadjuvant chemotherapy (10/18).
  • After six cycles of chemotherapy metastases to the peritoneum, Douglas' pouch, diaphragm, and liver serosa were higher in the CP group than the TP group (p < 0.05).
  • In conclusion, we suggest paclitaxel/carboplatin in peritoneal carcinomatosis of the ovary as a neoadjuvant chemotherapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Ovarian Neoplasms / drug therapy. Peritoneal Neoplasms / drug therapy
  • [MeSH-minor] Carboplatin / administration & dosage. Carcinoma, Endometrioid / drug therapy. Carcinoma, Endometrioid / pathology. Carcinoma, Endometrioid / surgery. Combined Modality Therapy. Cyclophosphamide / administration & dosage. Cystadenocarcinoma, Serous / drug therapy. Cystadenocarcinoma, Serous / pathology. Cystadenocarcinoma, Serous / surgery. Drug Administration Schedule. Female. Humans. Middle Aged. Neoadjuvant Therapy. Paclitaxel / administration & dosage. Prospective Studies. Salvage Therapy. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15032280.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 8N3DW7272P / Cyclophosphamide; BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


14. Matsutani T, Uchida E, Maruyama H, Suzuki S, Yokoyama T, Matsushita A, Hirakata A, Kawamoto M, Arai H, Umakoshi M, Wakabayashi H, Sasajima K: [A successful resected case of far-advanced cancer at the esophagogastric junction by chemoradiotherapy with docetaxel, nedaplatin and 5-fluorouracil]. Gan To Kagaku Ryoho; 2010 Oct;37(10):1949-52
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Computed tomography (CT) of the chest and abdomen showed invasion to the diaphragm.
  • He received radiation therapy (40 Gy/total, 2 Gy/day×20 times) in combination with chemotherapy using docetaxel (40 mg/m², day 1), nedaplatin (10mg/body, days 1-5) and 5-fluorouracil (500 mg/body, days 1-5).
  • After this combination chemoradiation therapy (CRT), macroscopic examinations showed significant reductions in the size of tumor, leading a partial response according to the RECIST guidelines.
  • He was treated on an outpatient basis without adjuvant therapy, and died 6 months after the operation by liver, spleen and lymph node metastases.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Esophageal Neoplasms / drug therapy. Esophagogastric Junction / pathology. Fluorouracil / therapeutic use. Organoplatinum Compounds / therapeutic use. Stomach Neoplasms / drug therapy. Taxoids / therapeutic use
  • [MeSH-minor] Aged. Biopsy. Combined Modality Therapy. Fatal Outcome. Humans. Male. Neoplasm Staging

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20948262.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Organoplatinum Compounds; 0 / Taxoids; 15H5577CQD / docetaxel; 8UQ3W6JXAN / nedaplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


15. Garofalo A, Valle M: Laparoscopy in the management of peritoneal carcinomatosis. Cancer J; 2009 May-Jun;15(3):190-5
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This procedure allows us to define with certainty the origin of the neoplasm, the peritoneal cancer index (PCI), the involvement of the small bowel and its mesentery, the feasibility of surgery and the index of attainable cytoreduction, the evaluation of an eventual multiorgan resection, and finally results in no mortality and very low morbidity.The indications for laparoscopy are as follows: staging of the carcinomatosis already diagnosed with imaging (CT scan and MRI), staging of carcinomatosis of dubious origin (biopsy), restaging after neoadjuvant chemotherapy, restaging during follow-up in the case of dubious imaging, and restaging after adjuvant chemotherapy.Open (Hasson) technique has always been used in the introduction of the first trocar, and the changing position of the surgical bed allows for the evaluation of all the abdominal quadrants, limiting viscerolysis to the essential minimum to avoid iatrogenic lesions.
  • Associating the intraoperative ultrasound has allowed us to reduce understaging of lesions at the depth of the diaphragm, of hepatic metastases and neoplastic masses at the pancreatic tail, and of the omental retrocavity.In all the cases in which diagnostic laparoscopy was followed by peritonectomy, we found a good correlation between open surgery data and the laparoscopic PCI.
  • Four complications were observed: 2 cases (1.02%) involved an infection of the trocar insertion site, which was treated with antibiotic therapy, and 2 cases (1.02%) involved diaphragm perforation and intraoperative bleeding, respectively, both resolved with videolaparoscopic technique.
  • There was no mortality and no port site metastasis.More recently, we have used videolaparoscopic surgery in the treatment of neoplastic ascites that did not respond to chemotherapy for palliative purposes, which resulted in the total disappearance of the ascites.
  • In 28 cases of neoplastic ascites nonrespondent to chemotherapy, we were able to implement fully laparoscopic hyperthermic chemotherapy for the palliative treatment of the ascites, with total disappearance of it in all cases.
  • The l-hyperthermic intraperineal chemotherapy was carried out at 42 degrees C for 90 minutes with 1.5% dextrose solution as a carrier.
  • The chemotherapy solution was cisplatin and doxorubicin, or mitomycin, depending on the type of primary tumor.
  • A computed tomography scan performed in follow-up showed a small, clinically undetectable, fluid accumulation in the pelvis of 1 patient.
  • Neither mortality nor morbidity was observed in connection with the procedure.
  • [MeSH-minor] Female. Humans. Male. Neoplasm Staging / methods. Treatment Outcome. Video Recording

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19556903.001).
  • [ISSN] 1528-9117
  • [Journal-full-title] Cancer journal (Sudbury, Mass.)
  • [ISO-abbreviation] Cancer J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


16. Christiansen S, Semik M, Dockhorn-Dworniczak B, Rötker J, Thomas M, Schmidt C, Jürgens H, Winkelmann W, Scheld HH: Diagnosis, treatment and outcome of patients with Askin-tumors. Thorac Cardiovasc Surg; 2000 Oct;48(5):311-5
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnosis, treatment and outcome of patients with Askin-tumors.
  • At the time of first diagnosis, five patients did not reveal any metastases.
  • One patient suffered from intrapulmonary metastases and two patients from an infiltration of the diaphragm and of adjacent vertebral bodies.
  • Treatment consisted of a pre- and postoperative (radio-) chemotherapy according to the EVAIA protocol and a radical tumor resection in all patients.
  • The postoperative course was uneventful in seven patients, one patient suffered from pneumonia after multiple wedge resections for intrapulmonary metastases.
  • Our data demonstrate that Askin tumors require an aggressive multimodality treatment consisting of pre- and postoperative chemotherapy, radical surgical resection and postoperative irradiation, which may be performed preoperatively in selected cases, too.
  • [MeSH-minor] Adolescent. Adult. Child. Combined Modality Therapy. Female. Humans. Male. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11100769.001).
  • [ISSN] 0171-6425
  • [Journal-full-title] The Thoracic and cardiovascular surgeon
  • [ISO-abbreviation] Thorac Cardiovasc Surg
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] GERMANY
  • [Number-of-references] 17
  •  go-up   go-down


17. Cohen-Mouly S, Badia A, Bats AS, Barthes F, Bensaïd C, Riquet M, Lécuru F: Role of video-assisted thoracoscopy in patients with ovarian cancer and pleural effusion. Int J Gynecol Cancer; 2009 Dec;19(9):1662-5
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVES: To evaluate the feasibility of video-assisted thoracoscopy (VAT) for staging advanced ovarian cancer, to measure the performance of preoperative computed tomography (CT) for diagnosing pleural metastases, to assess the correlation between pleural and abdominal involvement, and to measure the impact of VAT on patient management.
  • The reason for VAT was either to evaluate unilateral or bilateral pleural effusions (n = 15) or to evaluate pleural metastases after neoadjuvant chemotherapy (n = 1).
  • The rates of involvement of the hepatic pedicle, mesentery, and right side of the diaphragm were compared with the rate of pleural involvement.
  • RESULTS: The right side of the chest was examined 12 times; and the left side, 4 times.
  • There were no complications; 1 procedure was stopped because of ventilatory intolerance.
  • Video-assisted thoracoscopy identified metastases smaller than 1 cm in 5 patients and larger than 1 cm in 2 additional patients; there was no evidence of pleural involvement in 6 patients.
  • Computed tomography had 14% sensitivity and 25% specificity for pleural status determination, using VAT biopsy as the reference standard.
  • Pleural involvement did not correlate with involvement of the hepatic pedicle, mesentery, or right side of the diaphragm.
  • [MeSH-minor] Aged. Biopsy, Needle. Disease Progression. Feasibility Studies. Female. Humans. Middle Aged. Neoplasm Staging / methods. Pleural Neoplasms / diagnosis. Pleural Neoplasms / secondary. Pleural Neoplasms / surgery. Retrospective Studies. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Ovarian cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19955956.001).
  • [ISSN] 1525-1438
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


18. Woodward PJ, Hosseinzadeh K, Saenger JS: From the archives of the AFIP: radiologic staging of ovarian carcinoma with pathologic correlation. Radiographics; 2004 Jan-Feb;24(1):225-46
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Ovarian cancer is the deadliest gynecologic malignancy, with approximately 70% of patients having peritoneal involvement at the time of diagnosis.
  • Stages III and IV disease are considered advanced, with stage III ovarian cancer including diffuse peritoneal disease involving the upper abdomen and stage IV disease having distant metastases including hepatic lesions.
  • Common sites of intraperitoneal seeding include the omentum, paracolic gutters, liver capsule, and diaphragm.
  • Although computed tomography is the most common imaging modality used to stage ovarian cancer, magnetic resonance imaging has been shown to be equally accurate.
  • Early ovarian cancer is treated with comprehensive staging laparotomy, whereas advanced but operable disease is treated with primary cytoreductive surgery (debulking) followed by adjuvant chemotherapy.
  • Patients with unresectable disease may benefit from neoadjuvant (preoperative) chemotherapy before debulking.

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14730048.001).
  • [ISSN] 1527-1323
  • [Journal-full-title] Radiographics : a review publication of the Radiological Society of North America, Inc
  • [ISO-abbreviation] Radiographics
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 73
  •  go-up   go-down


19. Iwata T, Nishiyama N, Izumi N, Tsukioka T, Suehiro S: Metastatic monophasic synovial sarcoma of the pleura. Ann Thorac Cardiovasc Surg; 2007 Aug;13(4):258-61
Genetic Alliance. consumer health - Synovial sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Pleural metastasis of synovial sarcoma that originally developed in the soft tissue is a very rare entity.
  • An asymptomatic 25-year-old female, with a history of a resected synovial sarcoma in her left brachial muscle and pulmonary metastasectomy of the right lung, presented a small nodule in the periphery of the left lung on a routine chest-computed tomography.
  • Many small patchy red lesions were also found on the visceral pleura of the lung and parietal pleura of the diaphragm.
  • We diagnosed unresectable pleural metastases of synovial sarcoma and finished the operation after sampling another pulmonary pleural lesion.
  • The patient then underwent ifomide-based chemotherapy and survived for 3 years after her initial surgery.
  • Postoperative histopathological examination revealed a solid and bundle-like proliferation of a short spindle cell tumor with a monophasic pattern, which was diagnosed as a metastatic pleural synovial sarcoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17717503.001).
  • [ISSN] 1341-1098
  • [Journal-full-title] Annals of thoracic and cardiovascular surgery : official journal of the Association of Thoracic and Cardiovascular Surgeons of Asia
  • [ISO-abbreviation] Ann Thorac Cardiovasc Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


20. Maggi G, Casadio C, Cianci R, Rena O, Ruffini E: Trimodality management of malignant pleural mesothelioma. Eur J Cardiothorac Surg; 2001 Mar;19(3):346-50
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: From September 1998 to August 2000, 32 consecutive patients with histological diagnosis of MPM underwent trimodality therapy, including surgery followed by adjuvant chemotherapy and radiation therapy.
  • Surgery consisted of pleurectomy/decortication (P/D) or pleural-pericardial-pneumonectomy and diaphragm (PPPD).
  • Pre-operative staging according to the Brigham Staging System was accomplished using computed tomography (CT) and magnetic resonance imaging (MRI); patients with evident extrapleural spread were excluded.
  • RESULTS: Our series included 21 men and 11 women with a median age of 53.5 years (range 40-69).
  • Ten patients were at Stage II and all received a PPPD; 16 patients were at Stage III (under-staged pre-operatively): of these, nine patients presented extrapleural lymph node metastases (N2) and all received a PPPD, seven patients presented with chest wall or mediastinal invasion (T4) with macroscopic residual tumour, and all received a de-bulking P/D.
  • Twenty-seven patients out of 30 surviving surgery had a follow-up greater than 6 months; 21 patients out of 27 are alive with a median follow-up of 12.5 months. CONCLUSIONS:.
  • (1) Trimodality therapy is feasible in selected patients with MPM and has an acceptable operative mortality rate. (2) Our current pre-operative staging based on CT/MRI looks rather inaccurate and needs to be improved. (3) The high rate of post-surgical N2 patients or with diffusion to the inferior surface of the diaphragm may suggest the use of routine mediastinoscopy and laparoscopy for a more appropriate patient selection.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Mesothelioma / therapy. Pleural Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Carboplatin / administration & dosage. Chemotherapy, Adjuvant. Combined Modality Therapy. Female. Follow-Up Studies. Humans. Infusions, Intravenous. Male. Middle Aged. Paclitaxel / administration & dosage. Pneumonectomy / methods. Radiation Dosage. Radiotherapy, Adjuvant. Retrospective Studies. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11251277.001).
  • [ISSN] 1010-7940
  • [Journal-full-title] European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery
  • [ISO-abbreviation] Eur J Cardiothorac Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


21. Mehrabi A, Kashfi A, Schemmer P, Sauer P, Encke J, Fonouni H, Friess H, Weitz J, Schmidt J, Büchler MW, Kraus TW: Surgical treatment of primary hepatic epithelioid hemangioendothelioma. Transplantation; 2005 Sep 27;80(1 Suppl):S109-12
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgical treatment of primary hepatic epithelioid hemangioendothelioma.
  • It can develop in different tissues such as soft tissue, lung, or liver.
  • All patients in our series with confirmed histological HEH did not show extrahepatic extension and consequently underwent surgical treatment.
  • In one patient, a right-sided hemihepatectomy with partial resection of the diaphragm was performed.
  • No adjuvant chemotherapy was applied.
  • Until now, no recurrence of local tumor or distant metastases could be observed during follow-up in our series.
  • Early detection and surgical intervention in case of HEH can potentially offer curative treatment.
  • The treatment of first choice appears to be radical liver resection.
  • In our view, LTx represents a potentially important option for patients with a nonresectable tumor.
  • Despite the long waiting time, its often unclear dignity, and a proven progressive growth pattern, living related LTx also plays a potentially important role.
  • The role of adjuvant therapy currently remains unclear.
  • [MeSH-minor] Adult. Female. Humans. Middle Aged. Retrospective Studies. Survivors. Treatment Outcome

  • Genetic Alliance. consumer health - Hemangioendothelioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16286886.001).
  • [ISSN] 0041-1337
  • [Journal-full-title] Transplantation
  • [ISO-abbreviation] Transplantation
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down






Advertisement